





## UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.	
200,690	10/27/80	Johnson, et al	3427A-8	

Robert A.Armitage & John Kekich Patent Law Department The UpJohn Company Kalamazoo, MI 49001

Dentz

ART UNIT PAPER NUMBER

121 MAILED

This is a communication from the examiner in charge of your application.

COMMISSIONER OF PATENTS AND TRADEMARKS

MAR 18 1981

GROUP 120

Responsive to communication filed on			is action is made final.
A shortened statutory period for response to this action is set to expire month(s), Failure to respond within the period for response will cause the application to become abandon		leys from the dat J.S.C. 133	e of this letter.
Part I THE FOLLOWING ATTACHMENT(S) ARE PART OF THIS ACTION:			
	ormal Patent	Drawing, PTO-9	4.8
3. Notice of References Cited by Applicant, PTO-1449 4. Notice of Int	formal Patent	Application, Fo	
Part II SUMMARY OF ACTION 5. PT0-1142			
1. Palaims		are pending	in the application.
Of the above, claims		are withdraw	n from consideration.
2. Claims		have been ca	ncelled.
3. Claims		are allowed.	
4. UClaims		are rejected.	
5. Claims		are objected	to.
6. Claims	are subject	to restriction or	election requirement
7. The formal drawings filed on	are accepta	able.	
8. The drawing correction request filed on	has been	approved.	disapproved.
9. Acknowledgment is made of the claim for priority under 35 U.S.C. 119. The certified	d copy has		
been received.		· · · · · · · · · · · · · · · · · · ·	<del> </del>
filed on			
10. Since this application appears to be in condition for allowance except for formal mat cordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213.	ters, prosecut	tion as to the me	rits is closed in ac-
11. Other			

NOTIFICATION OF REJECTION(S) AND/OR OBJECTION(S) (35 USC 132)  CLAIMS PRANCHE PORT REPERENCES TO IDENTIFICATION AND COMMENTS  (1) REJECTION  (1) REPERTIENT  (2) Over Count and Claims of Pathology applicants (2) Entry and Claims of Pathology applicants (2) Entry and Claims of Pathology applicants (2) Entry and Claims of Pathology and the specific intended use of Desire and the specific intended use of Desire and Cont. in par. 5)  3 Moncada et al. cited by applicants is made of record.  6 must be recited. Consisting enantially of Pathology and Consisting enantially of Pathology and Consisting and Cons		142 (10-78)			U.S. DEPARTMENT OF COMMERCE Patent and Trademark Office			
NOTIFICATION OF REJECTION(S) AND/OR OBJECTION(S) (35 USC 132)  CLAIMS REJECTION REFERENCES * IDENTIFICATION AND COMMENTS (1) PROPERTY (	·				PART III SERIAL 2006 90 GROUP ART UNIT			
CLAIMS PRESENTE ON REFERENCES * 10 PRINTIPORMATION AND COMMENTS OF PARTIES AND CONTROL (1)  1 Clarking applicants' corporating Ser. No. 8199.  1 Clarking applicants' corporating Ser. No. 8199.  1 Clarking applicants' corporating Ser. No. 8199.  The amount of the cicture ingradient and the specific intended use of the pharmaceutical compusition of class (Cont. in par. 5).  3 Moncada et al. cited by applicants is made of record.  6 must be secited. Consisting essentially of renders claims 1-5 indefinite. What are the other ingredients.								
10 Portolog Over Count and claims of Patenting applicants' copending Ser. No. 8199.  1 Polarting applicants' copending Ser. No. 8199.  1-6 35 USC 117 The amount of the cature ingradient and the specific intended use of the pharmaceutical composition of class (Cont. in par. 5).  3 Moncada et al. cited by applicants is made of record.  6 must be recited. Consisting essentially of randers claims 1-5 indefinite. What are the other ingredients.		-	_					
1 Palenting applicants' coppending Ser. No. 8199.  1-6 35 USC 112 The amount of the active ingredies  2 and the specific intended use of the pharmaceutical compusition of class (Cont. in par. 5)  3  4  5 Menicada et. al. cited by applicants is made of record.  6 must be recited. "Consisting essentially of renders claims 1-5 indefinite. What are the ingredients.			REJECTION		IDENTIFICATION AND COMMENTS			
The amount of the active ingredient of the active ingredient and the specific intended use of the pharmaceutical computation of class (Cont. in par. 5)  Moncada et al. cited by applicants in made of record.  6 must be racited. Consisting essentially of renders claims 1-5 indefinite. What are the other ingredients.		1-6	Darle		Over Count and alive			
The amount of the active ingredient and the specific intended use of the pharmaceutical computation of class (Cent. in par. 5)  Moncada et al. cited by applicants in made of record.  6 must be racited. Consisting essentially of renders claims 1-5 indefinite. What are the ingredients.			Patation		and the state of No Sigger			
5 Moncada et al. cited by applicants is made of record.  6 must be recited. "Consisting enantially of renders claims 1-5 indefinite. What are the ingredients.	1		, wineing		applicants coppending ser. 1.0. 01.71			
5 Moncada et al. cited by applicants is made of record.  6 must be recited. "Consisting enantially of renders claims 1-5 indefinite. What are the ingredients.					·			
5 Moncada et al. cited by applicants is made of record.  6 must be recited. "Consisting enantially of renders claims 1-5 indefinite. What are the ingredients.			2/5/450		The American American			
5 Moncada et al. cited by applicants is made of record.  6 must be recited. "Consisting enantially of renders claims 1-5 indefinite. What are the ingredients.		1-6	73 USC112		the amount of the active ingradient			
5 Moncada et al. cited by applicants is made of record.  6 must be recited. "Consisting enantially of renders claims 1-5 indefinite. What are the ingredients.	2.	``			and the specific intended use of the			
5 Moncada et al cited by applicants is made of record.  6 must be recited. Consisting enantially of renders claims 1-5 indefinite. What are the other ingredients.					pharmaceutical composition of claim			
5 Moncada et al cited by applicants in made of record.  6 6 must be recited. Consisting enantially of renders claims 1-5 indefinite. What are the other ingredients.					(Eart. in par. 5)			
5 Moncada et al cited by applicants in made of record.  6 6 must be recited. Consisting enantially of renders claims 1-5 indefinite. What are the other ingredients.					,			
5 Moncada et. al. cited by applicants is made of record.  6 must be recited. Consisting essentially of renders claims 1-5 indefinite. What are the other ingredients.	3				· · · · · · · · · · · · · · · · · · ·			
5 Moncada et. al. cited by applicants is made of record.  6 must be recited. Consisting essentially of renders claims 1-5 indefinite. What are the other ingredients.								
5 Moncada et. al. cited by applicants is made of record.  6 must be recited. Consisting essentially of renders claims 1-5 indefinite. What are the other ingredients.					·			
5 Moncada et. al. cited by applicants is made of record.  6 must be recited. Consisting essentially of renders claims 1-5 indefinite. What are the other ingredients.								
made of record.  6 6 must be recited. Consisting essentially of renders claims 1-5 indefinite. What are the other ingredients.	4							
made of record.  6 must be recited. Consisting essentially of renders claims 1-5 indefinite. What are the other ingredients.								
made of record.  6 must be recited. Consisting essentially of renders claims 1-5 indefinite. What are the other ingredients.								
made of record.  6 6 must be recited. Consisting essentially of renders claims 1-5 indefinite. What are the other ingredients.								
renders claims 1-5 indefinite. What are the other ingredients.	5		Monca	da et.	al cited by applicants in			
renders claims 1-5 indefinite. What are the other ingredients.		made		record.				
renders claims 1-5 indefinite. What are the other ingredients.					·			
renders claims 1-5 indefinite. What are the other ingredients.	6	6	must	la 201	ital "Consisting and tille of			
		muse de rocitor. Unsisting essantially of						
		Lenders claims 1-5 indéfinite. What are						
	the older ingredients.							
					· · · · · · · · · · · · · · · · · · ·			
		-						
					+			
* Capital letters representing references are identified on accompanying Form PTO-892  The symbol "v" between letters represents - in view of								
The symbol "+" or "%" between letters represents - and  A slash "/" between letters represents the alternative - or -								
NOTE: Sections 100, 101, 102, 103, and 112 of the Patent Statute	NOT							
(Title 35 of the United States Code) are reproduced on the back of this sheet.								
		•						

35 U.S.C. 100. Definitions. When used in this title unless the context otherwise indicates —

(a) The term "invention" means invention or discovery.

(b) The term "process" means process, art or method, and includes a new use of a known process, machine, manufacture, composition of matter, or material.

(c) The terms "United States" and "this country" mean the United States of America, its territories and possessions.

(d) The word "patentee" includes not only the patentee to whom the patent was issued but also the successors in title to the patentee.

35 U.S.C. 101. Inventions patentable. Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

35 U.S.C. 102. Conditions for patentability; novelty and loss of right to patent. A person shall be entitled to a patent unless —

(a) the invention was known or used by others in this country, or patented or described in a printed publication is this or a foreign country, before the invention thereof by the applicant for patent, or

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of the application for patent in the United States, or

(c) he has abandoned the invention, or

(d) the invention was first patented or cause to be patented by the applicant or his legal representatives or assigns in a foreign country prior to the date of the application for patent in this country on an application filed more than twelve months before the filing of the application in the United States, or

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or.

(f) he did not himself invent the subject matter sought to be patented, or

(g) before the applicant's invention thereof the invention was made in this country by another who had not abandoned, suppressed, or concealed it. In determining priority of invention there shall be considered not only the respective dates of conception and reduction to practice of the invention, but also the reasonable diligence of one who was first to conceive and last to reduce to practice, from a time prior to conception by the other.

35 U.S.C. 103. Conditions for patentability; non-obvious subject matter. A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

35 U.S.C. 112. Specification. The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. A claim may be written in independent or dependent form, and if in dependent form, it shall be construed to include all the limitations of the claim incorporated by reference into the dependent claim.

An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof.